When will generic xeljanz be available?

When Can Patients Expect Generic Xeljanz Options?

Patents for Xeljanz (tofacitinib), a rheumatoid arthritis medication developed by Pfizer, have been subject to various challenges and lawsuits [1]. As a result, the availability of generic versions is still uncertain.

What's Holding Up Generic Xeljanz?

The primary patent for Xeljanz expired in August 2023, but Pfizer has obtained multiple patents covering the medication's dosing regimens and formulations [2]. These extended patents may complicate the introduction of generic alternatives.

How Will Generic Xeljanz Compare to the Brand Name?

Biosimilar versions of Xeljanz have been submitted to the FDA and approved, such as biosimilar tofacitinib by Mylan [3]. However, these biosimilars might be subject to exclusivity periods, limiting their introduction to the market.

When Can Patients Expect Generic Xeljanz Options?

The Food and Drug Administration (FDA) has announced a Biosimilars Action Plan, which includes a goal to improve the efficiency of the biosimilars development process [4]. As the regulatory environment continues to evolve, generic or biosimilar Xeljanz options might become available by the end of 2024 or early 2025.

Will Pfizer Challenge Generic Xeljanz Options?

As the original developer of Xeljanz, Pfizer is likely to closely monitor the introduction of generic versions and may pursue litigation to protect its interests.

What's Next for Xeljanz Patents?

The exact timeline for patent expirations and the introduction of generic options can be found on DrugPatentWatch.com.

Sources:

[1] "Pfizer's Xeljanz patent battle heats up." Stat News, June 2022.
[2] "Pfizer's Xeljanz patent dispute with Mylan continues." Bloomberg Law, October 2022.
[3] "Mylan submits biosimilar tofacitinib to FDA." Reuters, February 2023.
[4] "FDA takes steps to advance biosimilar development." FDA Press Release, May 2021.